Jun Ho Yi

2.1k total citations
88 papers, 1.5k citations indexed

About

Jun Ho Yi is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Jun Ho Yi has authored 88 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 28 papers in Pathology and Forensic Medicine and 21 papers in Molecular Biology. Recurrent topics in Jun Ho Yi's work include Lymphoma Diagnosis and Treatment (24 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (8 papers). Jun Ho Yi is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), CNS Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (8 papers). Jun Ho Yi collaborates with scholars based in South Korea, China and United States. Jun Ho Yi's co-authors include Seok Jin Kim, Won Seog Kim, Bohong Guo, Do Hyoung Lim, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Rui Ling, Won Ki Kang and Young Suk Park and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jun Ho Yi

82 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jun Ho Yi South Korea 22 552 514 324 217 214 88 1.5k
Haiyan Yang China 23 498 0.9× 604 1.2× 347 1.1× 132 0.6× 404 1.9× 84 1.6k
Federica Saletta Australia 19 375 0.7× 779 1.5× 346 1.1× 129 0.6× 266 1.2× 38 1.5k
Cheng Ean Chee Singapore 18 465 0.8× 955 1.9× 302 0.9× 100 0.5× 203 0.9× 73 1.9k
Yong Xu China 26 461 0.8× 1.1k 2.2× 631 1.9× 161 0.7× 404 1.9× 83 2.1k
Jacinta Serpa Portugal 26 319 0.6× 1.1k 2.1× 501 1.5× 121 0.6× 257 1.2× 77 2.0k
Stefania Cannito Italy 29 440 0.8× 872 1.7× 582 1.8× 119 0.5× 203 0.9× 63 2.7k
Yunus A. Luqmani Kuwait 25 941 1.7× 1.2k 2.4× 606 1.9× 217 1.0× 265 1.2× 66 2.5k
Kee-Ho Lee South Korea 20 597 1.1× 1.2k 2.4× 296 0.9× 99 0.5× 119 0.6× 35 2.2k
Xinxin Zhang China 18 517 0.9× 684 1.3× 318 1.0× 86 0.4× 436 2.0× 76 1.5k

Countries citing papers authored by Jun Ho Yi

Since Specialization
Citations

This map shows the geographic impact of Jun Ho Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Ho Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Ho Yi more than expected).

Fields of papers citing papers by Jun Ho Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Ho Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Ho Yi. The network helps show where Jun Ho Yi may publish in the future.

Co-authorship network of co-authors of Jun Ho Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Ho Yi. A scholar is included among the top collaborators of Jun Ho Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Ho Yi. Jun Ho Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Park, Changhee, Ho Sup Lee, Ka‐Won Kang, et al.. (2024). Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature Communications. 15(1). 2776–2776. 6 indexed citations
3.
Huang, Xinping, Kui Wang, Renkai Wu, et al.. (2024). Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. 120(2). e791–e791. 1 indexed citations
4.
Lee, Ji Yun, Ji Hyun Kwon, Joon Young Hur, et al.. (2023). Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Research and Treatment. 56(2). 681–687. 4 indexed citations
5.
Jo, Jae‐Cheol, Young‐Woo Jeon, Deok‐Hwan Yang, et al.. (2023). A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea. Expert Opinion on Biological Therapy. 23(8). 737–747. 1 indexed citations
6.
Ti, Dongdong, et al.. (2023). The Role of Mesenchymal Stem/Stromal Cells Secretome in MacrophagePolarization: Perspectives on Treating Inflammatory Diseases. Current Stem Cell Research & Therapy. 19(6). 894–905. 3 indexed citations
7.
Kim, Mihee, Je‐Jung Lee, Chang‐Ki Min, et al.. (2023). Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Annals of Hematology. 102(8). 2233–2240. 1 indexed citations
8.
Jo, Jae‐Cheol, Yoo Jin Lee, Sang Eun Yoon, et al.. (2021). Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. Blood Cancer Journal. 11(12). 190–190. 14 indexed citations
9.
Jung, Sung‐Hoon, Young Rok, Dae Sik Kim, et al.. (2020). Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei Medical Journal. 61(6). 452–452.
10.
Song, Ga‐Young, Dok Hyun Yoon, Cheolwon Suh, et al.. (2020). Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplantation. 56(5). 1205–1208. 10 indexed citations
11.
Wu, Yanbin, Chao Zhang, Jian Wu, et al.. (2020). Quantitative determination of multi-class bioactive constituents for quality assessment of ten Anoectochilus, four Goodyera and one Ludisia species in China. Chinese Herbal Medicines. 12(4). 430–439. 16 indexed citations
12.
Kim, Seok Jin, Dok Hyun Yoon, Hye Jin Kang, et al.. (2019). Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer. 19(1). 20 indexed citations
13.
Yun, Jun, Jun Ho Yi, Xin Li, et al.. (2017). [TNF-α regulates the proliferation of human breast cancer cells via regulation of ceramide content].. PubMed. 33(10). 1303–1309. 3 indexed citations
14.
Choi, Jung Hye, Tae Min Kim, Hyo Jung Kim, et al.. (2017). Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01. Cancer Research and Treatment. 50(2). 590–598. 7 indexed citations
15.
Yi, Jun Ho, Seok Jin Kim, & Won Seog Kim. (2017). Brentuximab vedotin: clinical updates and practical guidance. Blood Research. 52(4). 243–243. 37 indexed citations
16.
Yao, Qin, Juxiang Chen, Yan Wang, et al.. (2015). Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer. Genetics and Molecular Research. 14(1). 2099–2103. 7 indexed citations
17.
Peng, Wen, et al.. (2013). Antimicrobial activity and cytotoxicity of endophytes from Scapania verrucosa Heeg.. Genetics and Molecular Research. 12(2). 916–924. 7 indexed citations
18.
Wang, Hui, Nanlin Li, Haifeng Jin, et al.. (2013). Steroidal saponin of Trillium tschonoskii. Reverses multidrug resistance of hepatocellular carcinoma. Phytomedicine. 20(11). 985–991. 36 indexed citations
19.
Chen, Xiaohong, Jun Yun, Fei Fei, et al.. (2012). Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathology - Research and Practice. 208(8). 437–443. 23 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haiyan Yang Breakdown of academic impact, for papers by Federica Saletta Breakdown of academic impact, for papers by Cheng Ean Chee Breakdown of academic impact, for papers by Yong Xu Breakdown of academic impact, for papers by Jacinta Serpa Breakdown of academic impact, for papers by Stefania Cannito Breakdown of academic impact, for papers by Yunus A. Luqmani Breakdown of academic impact, for papers by Kee-Ho Lee Breakdown of academic impact, for papers by Xinxin Zhang
Rankless by CCL
2026